GlassScriptPhysician profile
Kevin D Breniman
NPI 1659348498
$7,428.50
in general payments reported to CMS, 2019-2025
29 companies · $419 in 2025
The $419 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $265 · 2021: $698 · 2022: $380 · 2023: $4,206 · 2024: $1,113 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,178 · Food and Beverage: $2,559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,177.66 |
| Food and Beverage | $2,559.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $3,858.57 | 2021-2024 | Axonics, Bulkamid |
| Abbvie INC. | $970.04 | 2019-2025 | Lo Loestrin Fe |
| Caldera Medical, INC | $765.25 | 2023-2024 | Desara |
| Aspira Women'S Health INC | $201.10 | 2021-2022 | |
| Astellas Pharma US INC | $197.48 | 2022-2025 | Veozah |
| Allergan, INC. | $165.79 | 2019-2021 | |
| Davol INC. | $154.69 | 2022-2023 | Arista Ah Flexitip |
| Bayer Healthcare Pharmaceuticals INC. | $134.43 | 2019-2023 | |
| Organon LLC | $114.89 | 2021-2024 | Nexplanon |
| Coloplast Corp | $112.13 | 2020-2024 | |
| Intuitive Surgical, INC. | $101.17 | 2019 | |
| Mayne Pharma Commercial LLC | $100.42 | 2021-2025 | |
| Exeltis, USA INC. | $62.58 | 2021-2023 | Slynd |
| Avion Pharmaceuticals | $55.55 | 2019-2021 | |
| Shield Therapeutics INC | $45.24 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $42.88 | 2021 | |
| Therapeuticsmd, INC. | $42.65 | 2021-2022 | |
| Pfizer INC. | $39.17 | 2022-2023 | |
| Ethicon US, LLC | $38.28 | 2021 | |
| Minerva Surgical, INC | $37.91 | 2019-2025 | |
| Scynexis, INC. | $27.18 | 2022 | |
| Biogen, INC. | $26.60 | 2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $26.17 | 2019 | |
| Sumitomo Pharma America, INC. | $23.82 | 2024 | Myfembree |
| Boston Scientific Corporation | $23.28 | 2025 | Solyx Sis System |
| Laborie Medical Technologies Corp. | $18.67 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Meditrina | $16.09 | 2021 | |
| Agile Therapeutics, INC. | $13.35 | 2021 | |
| Lupin INC. | $13.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Breniman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.